Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States

References

• Estimated New Cancer Cases and Deaths for 2008. Atlanta, GA: American Cancer Society; 2008. Available at: http://seer.cancer. gov/csr/1975_2005/results_single/sect_01_table.01.pdf.
   Google Scholar
• The Non-Hodgkin Lymphoma Classification Project. A Clinical Evaluation of the International Lymphoma Study Group classification of non-Hodgkin lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon P A, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1: 45–50
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82
   PubMed Web of Science ®Google Scholar
• Greer J P, York J C, Cousar J B, Mitchell R T, Flexner J M, Collins R D, et al. Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases. J Clin Oncol 1984; 2: 788–798
   PubMed Web of Science ®Google Scholar
• Melnyk A, Rodriguez A, Pugh W C, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin lymphoma. Blood 1997; 89: 4514–4520
   PubMed Web of Science ®Google Scholar
• Rudiger T, Weisenburger D D, Anderson J R, Armitage J O, Diebold J, MacLennan K A, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin lymphoma classification project. Ann Oncol 2002; 13: 140–149
   PubMed Web of Science ®Google Scholar
• Savage K J, Chhanabhai M, Gascoyne R D, Connors J M. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467–1475
   PubMed Web of Science ®Google Scholar
• Groves F, Linet M, Travis L, SS D. Cancer surveillance series: non-Hodgkin lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240–1251
   PubMed Web of Science ®Google Scholar
• Armitage J O, Vose J M, Weisenburger D D. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004; 15: 1447–1449
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Stansfeld A G, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Chan J KC. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol 2001; 19: 129–150
   PubMed Web of Science ®Google Scholar
• Hastrup N, Hamilton-Dutoit S, Ralfkiaer E, Pallesen G. Peripheral T-cell lymphomas: an evaluation of reproducibility of the updated Kiel classification. Histopathology 1991; 18: 99–105
   PubMed Web of Science ®Google Scholar
• Pittaluga S, Bijnens L, Teodorovic I, Hagenbeek A, Meerwaldt J H, Somers R, et al. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood 1996; 87: 4358–4367
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Chan J K, Banks P M, Cleary M L, Delsol G, De Wolf-Peeters C, Falini B, et al. A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol 1995; 103: 543–560
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Cheung M M, Chan J K, Lau W H, Foo W, Chan P T, Ng C S, et al. Primary non-Hodgkin lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70–77
   PubMed Web of Science ®Google Scholar
• Ries L A, Harkins D, Krapcho M, Mariotto A, Miller B A, Feuer E J, et al. SEER Cancer Statistics Review, 1975–2003. National Cancer Institute, Bethesda, MD 2006
   Google Scholar
• Ries L A, Kosary C L, Hankey B F, Miller B A, Harras A, Edwards B K, et al. SEER Cancer Statistics Review, 1973–1994. National Cancer Institute, Bethesda, MD 1997
   Google Scholar
• Hankey B F, Ries L A, Edwards B K. The surveillance, epidemiology, and end results program: a National resource. Cancer Epidemiol Biomarkers Prev 1999; 8: 1117–1121
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov/publicdata). SEER*Stat Database: Incidence – SEER 11 Regs + AK Public-Use, Nov 2003 Sub for Expanded Races (1992–2001). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2004, based on the November 2003 submission.
   Google Scholar
• Percy C L, Berg J W, Thomas L B. Manual of Tumor Nomenclature and Coding. American Cancer Society, New York, NY 1968
   Google Scholar
• World Health Organization. ICD-O International Classification of Diseases for Oncology. World Health Organization, Geneva, Switzerland 1976
   Google Scholar
• Percy C L, Berg J W, Thomas L B. International Classification of Diseases for Oncology. 2nd ed. World Health Organization, Geneva, Switzerland 1990
   Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• Conversion of neoplasms by topography and morphology from the International Classification of Diseases for Oncology, second edition to International Classification of Diseases for Oncology, third edition. Cancer Statistics Branch, DCCPS, SEER Program, National Cancer Institute. Available at: http://seer.cancer.gov/tools/conversion/ICDO2-3manual.pdf 2001.
   Google Scholar
• Morton L M, Wang S S, Devesa S S, Hartge P, Weisenburger D D, Linet M S. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265–276
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov/publicdata). SEER*Stat Database: Incidence – SEER 13 Regs + AK Public-Use, Nov 2005 Sub for Expanded Races (1992–2003). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2006, based on the November 2005 submission.
   Google Scholar
• Ries L AG, Eisner M P, Kosary C L, Hankey B F, Miller B A, Clegg L, et al. SEER Cancer Statistics Review, 1975–2001. National Cancer Institute, Bethesda, MD 2004
   Google Scholar
• Tiwari R C, Clegg L X, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res 2006; 15: 547–569
   PubMed Web of Science ®Google Scholar
• Medeiros L J, Jaffe E S, Chen Y Y, Weiss L M. Localization of Epstein-Barr viral genomes in angiocentric immunoproliferative lesions. Am J Surg Pathol 1992; 16: 439–447
   PubMed Web of Science ®Google Scholar
• de Bruin P C, Jiwa M, Oudejans J J, van der Valk P, van Heerde P, Sabourin J C, et al. Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. Blood 1994; 83: 1612–1618
   PubMed Web of Science ®Google Scholar
• Jaffe E S. Nasal and nasal-type T/NK-cell lymphoma: a unique form of lymphoma associated with the Epstein-Barr virus. Histopathology 1995; 27: 581–583
   PubMed Web of Science ®Google Scholar
• Kanavaros P, Lescs M C, Briere J, Divine M, Galateau F, Joab I, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81: 2688–2695
   PubMed Web of Science ®Google Scholar
• Bagdi E, Diss T C, Munson P, Isaacson P G. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 1999; 94: 260–264
   PubMed Web of Science ®Google Scholar
• Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, et al. Refractory sprue, coeliac disease and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208
   PubMed Web of Science ®Google Scholar
• Gale J, Simmonds P D, Mead G M, Sweetenham J W, Wright D H. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000; 18: 795–803
   PubMed Web of Science ®Google Scholar
• Gardner R V, Velez M C, Ode D L, Lee J W, Correa H. Gamma/delta T-cell lymphoma as a recurrent complication after transplantation. Leuk Lymphoma 2004; 45: 2355–2359
   PubMed Web of Science ®Google Scholar
• Khan W A, Yu L, Eisenbrey A B, Crisan D, al Saadi A, Davis B H, et al. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am J Clin Pathol 2001; 116: 41–50
   PubMed Web of Science ®Google Scholar
• Walsh S V, Egan L J, Connolly C E, Stevens F M, Egan E L, McCarthy C F. Enteropathy-associated T-cell lymphoma in the West of Ireland: low-frequency of Epstein-Barr virus in these tumors. Mod Pathol 1995; 8: 753–757
   PubMed Web of Science ®Google Scholar
• Chan J K. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol 2001; 19: 129–150
   PubMed Web of Science ®Google Scholar
• Jamal S, Picker L J, Aquino D B, McKenna R W, Dawson D B, Kroft S H. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol 2001; 116: 512–526
   PubMed Web of Science ®Google Scholar
• Nakamura S, Katoh E, Koshikawa T, Yatabe Y, Nagasaka T, Ishida H, et al. Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese. Pathol Int 1997; 47: 38–53
   PubMed Web of Science ®Google Scholar
• Suzumiya J, Ohshima K, Takeshita M, Kanda M, Kawasaki C, Kimura N, et al. Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. Leuk Lymphoma 1999; 35: 567–578
   PubMed Web of Science ®Google Scholar
• Kanegane H, Bhatia K, Gutierrez M, Kaneda H, Wada T, Yachie A, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood 1998; 91: 2085–2091
   PubMed Web of Science ®Google Scholar
• DePinho R A. The age of cancer. Nature 2000; 408: 248–254
   PubMed Web of Science ®Google Scholar
• McMurray M A, Gottschling D E. An age-induced switch to a hyper-recombinational state. Science 2003; 301: 1908–1911
   PubMed Web of Science ®Google Scholar
• Boren E, Gershwin M E. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004; 3: 401–406
   PubMed Web of Science ®Google Scholar
• Coussens L M, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a Study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Swenson W T, Wooldridge J E, Lynch C F, Forman-Hoffman V L, Chrischilles E, Link B K. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019–5026
   PubMed Web of Science ®Google Scholar
• Vose J M. Update on T-cell lymphoma. Ann Oncol 2008; 19: iv74–76
   PubMed Web of Science ®Google Scholar
• Clarke C A, Undurraga D M, Harasty P J, Glaser S L, Morton L M, Holly E A. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 2006; 15: 630–638
   PubMed Web of Science ®Google Scholar
• Savage K J, Harris N L, Vose J M, Ullrich F, Jaffe E S, Connors J M, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496–5504
   PubMed Web of Science ®Google Scholar